外用5%咪喹莫特乳膏治疗鲍恩病：回顾性研究
Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study.
作者信息
Rosen Ted, Harting Mandy, Gibson Marian
机构信息
Michael E. DeBakey VA Medical Center and Department of Dermatology, Baylor College of Medicine, Houston, Texas 77005, USA.
出版信息
Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2. doi: 10.1111/j.1524-4725.2007.33089.x.
BACKGROUND
Topical 5% imiquimod cream is an FDA-approved treatment for superficial basal cell carcinomas. It has also been utilized in the treatment of Bowen's disease (squamous cell in situ). The current literature on this subject, however, is scant, and this treatment is only validated by case reports and two small open label studies.
OBJECTIVE
The objective was to assess the efficacy of topical 5% imiquimod cream in the treatment of squamous cell in situ in a larger open-label case series. METHODS A retrospective study of 49 patients was performed.
RESULTS
Forty-two of the 49 (86%) patients in the study had a complete response with topical imiquimod. The remaining 7 (14%) failed therapy and required additional treatments. The mean follow-up duration was 19 months, with a range of 1 to 44 months.
CONCLUSION
Topical 5% imiquimod cream appears to be clinically beneficial in the treatment of Bowen's disease and should be considered as a treatment option.
背景
外用5%咪喹莫特乳膏是一种经美国食品药品监督管理局（FDA）批准用于治疗浅表性基底细胞癌的药物。它也被用于治疗鲍温病（原位鳞状细胞癌）。然而，目前关于这一主题的文献很少，这种治疗方法仅通过病例报告和两项小型开放标签研究得到验证。
目的
目的是在一个更大的开放标签病例系列中评估外用5%咪喹莫特乳膏治疗原位鳞状细胞癌的疗效。方法：对49例患者进行回顾性研究。
结果
该研究中49例患者中有42例（86%）外用咪喹莫特后完全缓解。其余7例（14%）治疗失败，需要额外治疗。平均随访时间为19个月，范围为1至44个月。
结论
外用5%咪喹莫特乳膏在治疗鲍温病方面似乎具有临床益处，应被视为一种治疗选择。
Zotero 插件